INSP
Inspire Medical Systems, Inc.
$61.44
+0.62
(+1.02%)
Mkt Cap
1.78B
Volume
517,994
52W Range
38.91-147.03
Sector
Healthcare
Beta
0.67
EPS (TTM)
4.66 USD
P/E Ratio
13.18
Revenue (TTM)
898.74M USD
Rev Growth (5Y)
+51.2%
EPS Growth (5Y)
N/A
AlphaVal · Fair Value
What we estimate one share is worth
$9.75
Overvalued
strong signal
530.2% above fair value
Modeled from cash flows & growth.
AlphaQuality · Grade · Gated
How strong & durable the business is
F
Platform & Compounding FCF
30.0 / 100 pillar composite (overridden)
A platform business that compounds free cash flow — graded A–F vs. similar companies.
Company Description
Inspire Medical Systems, Inc. operates as a medical technology enterprise, concentrating on the development and commercialization of advanced, minimally intrusive therapies for patients diagnosed with obstructive sleep apnea (OSA) across both domestic U.S. and international markets. A cornerstone of its product portfolio is the Inspire system, an innovative neurostimulation solution that offers a safe and proven effective treatment for individuals experiencing moderate to severe forms of OSA. Additionally, the company is pioneering a novel, closed-loop technology designed to continuously track a patient's breathing patterns and administer mild stimulation to the hypoglossal nerve, thereby maintaining an open airway. Founded in 2007, Inspire Medical Systems maintains its corporate headquarters in Golden Valley, Minnesota.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 911.98M | 802.80M | 624.80M | 407.86M | 233.39M | 115.38M | 82.05M | 50.59M | 28.57M | 16.43M | 8.01M |
| Net Income | 145.42M | 53.51M | (21.15M) | (44.88M) | (42.04M) | (57.20M) | (33.24M) | (21.83M) | (17.51M) | (18.53M) | (21.34M) |
| EPS | 4.95 | 1.80 | -0.72 | -1.60 | -1.54 | -2.19 | -1.40 | -1.50 | -1.30 | -1.49 | -1.71 |
| Free Cash Flow | 78.48M | 91.12M | 1.02M | 2.47M | (24.79M) | (55.50M) | (35.59M) | (18.94M) | (16.20M) | (18.25M) | (22.60M) |
| FCF / Share | 2.67 | 3.06 | 0.03 | 0.09 | -0.91 | -2.13 | -1.49 | -1.30 | -1.20 | -1.46 | -1.81 |
| Operating CF | 116.98M | 130.25M | 24.65M | 11.57M | (20.12M) | (53.05M) | (32.85M) | (18.69M) | (15.79M) | (17.95M) | (22.25M) |
| Total Assets | 907.32M | 808.38M | 676.81M | 564.88M | 295.08M | 281.19M | 181.25M | 200.08M | 25.09M | 13.12M | N/A |
| Total Debt | 32.16M | 31.79M | 24.85M | 16.41M | 34.09M | 30.63M | 25.35M | 24.93M | 16.46M | 15.69M | N/A |
| Cash & Equiv | 104.81M | 150.15M | 185.54M | 441.59M | 214.47M | 190.52M | 22.86M | 97.29M | 8.96M | 6.68M | N/A |
| Book Value | 781.16M | 689.70M | 572.51M | 496.01M | 229.05M | 229.75M | 139.84M | 164.00M | 1.48M | (6.61M) | N/A |
| Return on Equity | 0.19 | 0.08 | -0.04 | -0.09 | -0.18 | -0.25 | -0.24 | -0.13 | -11.80 | N/A | N/A |
| Metric | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 200.58M | 204.58M | 269.08M | 224.50M | 217.09M | 201.32M | 239.72M | 203.19M | 195.88M | 164.01M | 192.51M | 153.30M |
| Net Income | 314,000 | (11.29M) | 136.09M | 9.93M | (3.59M) | 2.99M | 35.22M | 18.50M | 9.79M | (10.01M) | 14.76M | (8.54M) |
| EPS | 0.01 | -0.39 | 4.70 | 0.34 | -0.12 | 0.10 | 1.18 | 0.62 | 0.33 | -0.34 | 0.50 | -0.29 |
| Free Cash Flow | 14.07M | 3.12M | 41.81M | 58.09M | (6.31M) | (15.11M) | 62.15M | 44.28M | (12.47M) | (2.84M) | 9.23M | (3.35M) |
| FCF / Share | 0.49 | 0.11 | 1.44 | 1.98 | -0.21 | -0.51 | 2.08 | 1.48 | -0.42 | -0.10 | 0.31 | -0.11 |
| Operating CF | 23.23M | 12.85M | 52.47M | 68.53M | 2.68M | (6.70M) | 69.18M | 52.28M | (78,000) | 8.86M | 17.27M | 3.64M |
| Total Assets | 925.99M | 911.38M | 918.49M | 807.72M | 802.19M | 730.81M | 808.38M | 796.19M | 728.39M | 685.84M | 676.81M | 639.49M |
| Total Debt | 29.09M | 29.55M | 62.15M | 32.58M | 33.06M | 33.52M | 31.79M | 25.33M | 24.51M | 24.50M | 24.85M | 25.17M |
| Cash & Equiv | 127.76M | 98.93M | 104.81M | 112.84M | 106.93M | 53.88M | 150.15M | 147.51M | 188.03M | 175.42M | 185.54M | 329.90M |
| Book Value | 825.58M | 792.34M | 781.16M | 666.46M | 677.81M | 635.74M | 689.70M | 696.56M | 638.07M | 589.02M | 572.51M | 544.18M |
| Return on Equity | 0.00 | -0.01 | 0.17 | 0.01 | -0.01 | 0.00 | 0.05 | 0.03 | 0.02 | -0.02 | 0.03 | -0.02 |
INSP News
Inspire Medical Systems, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference
ADAR1 Capital Management LLC Takes Position in Inspire Medical Systems, Inc. $INSP
Bank of America Corp DE Trims Stock Holdings in Inspire Medical Systems, Inc. $INSP
Deutsche Bank AG Makes New $7.86 Million Investment in Inspire Medical Systems, Inc. $INSP
INSP Stock Rallies Nearly 40% YTD: Can Its Growth Story Continue?
Here's Why You Should Add INSP Stock to Your Portfolio Now
Contrasting Medacta Group (OTCMKTS:MEDGF) & Inspire Medical Systems (NYSE:INSP)
New Strong Buy Stocks for August 18th
Assenagon Asset Management S.A. Increases Holdings in Inspire Medical Systems, Inc. $INSP
Is INSP a Buy as Margins Improve but Reimbursement Risks Persist?